Medivir B

Medivir reports liquidity of SEK 253.5m for Q2 2026 following an oversubscribed targeted share issue of about SEK 140m gross, which finances all three planned Phase II studies and, according to management, provides cash runway at least until 2030. The company recorded net revenue of SEK 1.2m and an operating loss of SEK 21.2m, a slight improvement year‑on‑year. Key pipeline milestones include publication of Fostrox data in Clinical Cancer Research, first patient treated in the FLEX‑HCC study in Korea, and expansion of MIV‑711 into Perthes disease. The stock reacted positively and rose sharply at times, with investors focusing on the improved financial position and clinical progress. » Más en de.investing.com

Medivir improved its operating result in the first quarter of 2026: the loss narrowed to -9.4 million SEK, a 30% improvement year-on-year, on net sales of 1.0 million SEK (+40%). Total operating costs fell 26% to 10.0 million SEK and cash position amounted to 149.1 million SEK. The company continues to focus on its Fostrox program (market potential ~2.5 billion USD for advanced HCC) and MIV-711 to address an unmet medical need in osteogenesis imperfecta. » Más en de.investing.com

Medivir reported revenue of SEK 1 million in the first quarter, a reduced EBITDA loss of SEK 8.80 million and an adjusted free cash flow of SEK -13 million. In February the company completed a directed share issue of SEK 45 million; cash and cash equivalents rose to SEK 149.1 million at the end of the quarter. Medivir plans to start a phase-2 proof-of-concept study for MIV-711 in osteogenesis imperfecta and a randomized second-line study of Fostrox in liver cancer; results from a veterinary study of MIV-701 are expected in Q4 2026. » Más en de.investing.com